Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Market Worth In Excess Of $1bn
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
You may also be interested in...
The Irish firm's CEO told Scrip about a transformative deal for Amryt, creating an international business with revenues of nearly $140m.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.